GSK0660 is a selective PPARdelta antagonist. GSK0660 differentially regulated 273 transcripts in TNFalpha-treated cells compared to TNFalpha alone. A pathway analysis revealed the enrichment of cytokine-cytokine receptor signaling. In particular, GSK0660 blocks the TNFalpha-induced upregulation of CCL8, a chemokine involved in leukocyte recruitment. GSK0660 blocks the effect of TNFalpha on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CCL17, and CXCL10 and it may therefore block TNFalpha-induced retinal leukostasis.
Puffer:
Powder
CAS Nummer:
[1014691-61-2]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
